文献速递脑血管病

英国先进影像筛选后超6小时机械取栓的成本效果分析

Exploring the Cost-Effectiveness of Mechanical Thrombectomy Beyond 6 Hours Following Advanced Imaging in the United Kingdom.
PubMed 文献 · Stroke · 2019-10-22

本研究基于英国疑似卒中患者(71岁、首次事件)建立决策树与马尔可夫模型,比较先进影像筛选下6小时内及超6小时取栓与仅常规影像筛选下6小时内取栓两种路径的成本效果。

要点

  • 先进影像筛选下超6小时取栓可能具有良好成本效果。
  • 先进影像特异度下降会影响增量成本效果比。

核心结论

  • 基于先进影像筛选的超6小时机械取栓可能物有所值。
  • 在充分评估其成本效果前,仍需关于先进影像实施及超6小时取栓获益先验概率的额外数据。

研究设计与样本

  • 研究建立决策树与马尔可夫模型,模拟英国疑似卒中患者队列,年龄71岁、首次事件。
  • 成本、健康结局与概率来自文献, outcomes 包括成本、生命年、质量调整生命年与增量成本效果比。
  • 进行了概率敏感性分析,并设置超6小时取栓获益先验概率10%、20%、30%及先进影像完美准确、80%灵敏度、70%特异度等情景。

主要发现

  • 先进影像准确度仅在其特异度下降时影响增量成本效果比。
  • 在终生 horizon 内,所有包含超6小时取栓的情景均改善QALYs与生命年。

临床怎么用

  • 在英国,对症状发作6小时后评估的急性缺血性卒中患者,若先进影像显示可挽救脑组织,机械取栓可获资助至12小时。

局限性

  • 关于先进影像实施及超6小时取栓获益先验概率的额外数据仍需获取,才能完全评估其成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- In the United Kingdom, mechanical thrombectomy (MT) for acute ischemic stroke patients assessed beyond 6 hours from symptom onset will be commissioned up to 12 hours provided that advanced imaging (AdvImg) demonstrates salvageable brain tissue. While the accuracy of AdvImg differs across technologies, evidence is limited regarding the proportion of patients who would benefit from late MT. We compared the cost-effectiveness of 2 care pathways: (1) MT within and beyond 6 hours based on AdvImg selection versus (2) MT only within 6 hours based on conventional imaging selection. The impact of varying AdvImg accuracy and prior probability for acute ischemic stroke patients to benefit from late MT was assessed. Methods- A decision tree and a Markov trace were developed. A hypothetical United Kingdom cohort of suspected stroke patients aged 71 years with first event was modeled. Costs, health outcomes, and probabilities were obtained from the literature. Outcomes included costs, life years (LYs), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios. Probabilistic sensitivity analyses were performed. Various scenarios with prior probabilities of 10%, 20%, and 30%, respectively, for acute ischemic stroke patients to benefit from late MT, and with perfect accuracy, 80% sensitivity, and 70% specificity of AdvImg were studied. Results- Incremental cost-effectiveness ratios resulting from our deterministic analyses varied from $8199 (£6164) to $49 515 (£37 229) per QALY gained. AdvImg accuracy impacted the incremental cost-effectiveness ratio only when its specificity decreased. Over lifetime horizons, all scenarios including late MT improved QALYs and LYs. Depending on the scenario, the probabilistic sensitivity analyses showed probabilities varying between 46% and 93% for the late MT pathway to be cost-effective at a willingness to pay threshold of $39 900 (£30 000) per QALY. Conclusions- Late MT based on AdvImg selection may be good value for money. However, additional data regarding the implementation of AdvImg and prior probability to benefit from late MT are needed before its cost-effectiveness can be fully assessed.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Peultier AC, Redekop WK, Allen M, et al. Exploring the Cost-Effectiveness of Mechanical Thrombectomy Beyond 6 Hours Following Advanced Imaging in the United Kingdom. Stroke. 2019. PMID: 31637975. doi:10.1161/STROKEAHA.119.026816

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。